A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
A Phase 2, Randomized, Observer-Blind, Dose Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
This study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to <12 years to determine the optimal dose level per age group.
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljerad beskrivning
mRNA-1283 will be administered at 2 different dose levels (Dose Level 1 and Dose Level 2), with mRNA-1273 serving as the active comparator. Dose Level 1 will be the lower dose, and Dose Level 2 will be the higher dose.
The study will consist of 2 cohorts. In Cohort 1, mRNA-1283 will be administered as a single dose to participants aged ≥2 to <12 years, regardless of prior coronavirus disease 2019 (COVID-19) vaccination status, with mRNA-1273 included as a comparator. In Cohort 2, mRNA-1283 will be administered as a 2-dose series to participants aged ≥6 months to <2 years who are previously unvaccinated for COVID-19, with mRNA-1273 included as a comparator.
Studietyp
Studietyp
Inskrivning (Beräknad)
Inskrivning
Fas
Fas
- Fas 2
Kontakter och platser
Studiekontakt
Studiekontakt
- Namn: Moderna WeCare Team
- Telefonnummer: 1-866-663-3762
- E-post: WeCareClinicalTrials@modernatx.com
Studieorter
-
-
Buenos Aires
-
Ciudad Autonoma, Buenos Aires, Argentina
- Har inte rekryterat ännu
- Fundacion Respirar - Consultorios Medicos Dra De Salvo
-
-
Santa Fe Province
-
Casilda, Santa Fe Province, Argentina
- Har inte rekryterat ännu
- Instituto Medico de la Fundacion Estudios Clinicos
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentina
- Har inte rekryterat ännu
- Hospital del Nino Jesus
-
-
-
-
Distrito Nacional (Santo Domingo)
-
Cristo Rey, Distrito Nacional (Santo Domingo), Dominikanska republiken, 10501
- Har inte rekryterat ännu
- Medvacplus Srl Fundacion Clinica Cruz Jiminian
-
Santo Domingo, Distrito Nacional (Santo Domingo), Dominikanska republiken, 10306
- Har inte rekryterat ännu
- Instituto Dermatologico y Cirugia de Piel ''Dr. Huberto Bogaert Diaz'' (IDCP-DHBD)
-
-
La Altagracia Province
-
Salvaleón de Higüey, La Altagracia Province, Dominikanska republiken
- Har inte rekryterat ännu
- Hospital General y de Especialidades Nuestra Señora de la Altagracia
-
-
Nacional
-
Santo Domingo, Nacional, Dominikanska republiken, 11901
- Har inte rekryterat ännu
- Hospital Materno Infantil San Lorenzo De Los Mina
-
-
-
-
California
-
Ontario, California, Förenta staterna, 91762
- Rekrytering
- Orange County Research Center
-
-
Florida
-
Miami, Florida, Förenta staterna, 33166
- Rekrytering
- Hope Research Network
-
Miami, Florida, Förenta staterna, 33167
- Rekrytering
- Spotlight Research Center - Internal Medicine
-
Miami Lakes, Florida, Förenta staterna, 33016
- Rekrytering
- Indago Research and Health Cen
-
Tamarac, Florida, Förenta staterna, 33321
- Rekrytering
- MplusM - D&H Tamarac Research Center
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60621
- Har inte rekryterat ännu
- Eagle Clinical Research, LLC
-
-
Michigan
-
Southfield, Michigan, Förenta staterna, 48075
- Rekrytering
- Great Lakes Research Institute -Southfield
-
-
Ohio
-
South Euclid, Ohio, Förenta staterna, 44121
- Har inte rekryterat ännu
- Senders Pediatrics
-
-
Texas
-
Beaumont, Texas, Förenta staterna, 77701
- Rekrytering
- REX Clinical Trials
-
Brownsville, Texas, Förenta staterna, 78520
- Rekrytering
- PanAmerican Clinical Research, LLC.
-
-
Utah
-
South Ogden, Utah, Förenta staterna, 84403
- Rekrytering
- South Ogden Family Medicine
-
-
Virginia
-
Richmond, Virginia, Förenta staterna, 23226
- Rekrytering
- Clinical Research Partners
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98105
- Har inte rekryterat ännu
- Childrens Hospital Regional Medical Center
-
-
-
-
Jalisco
-
Guadalajara, Jalisco, Mexiko
- Har inte rekryterat ännu
- Centro de Investigacion Clínica y Medicina Traslacional (CIMeT)
-
-
Mexico City
-
Mexico City, Mexico City, Mexiko
- Har inte rekryterat ännu
- Hospital Infantil de México Federico Gómez - Pediatric Gastroenterology
-
Mexico City, Mexico City, Mexiko
- Har inte rekryterat ännu
- Instituto Nacional de Pediatria
-
-
Querétaro
-
Querétaro City, Querétaro, Mexiko
- Har inte rekryterat ännu
- PanAmerican Clinical Research - Queretaro
-
-
Yucatán
-
Tizimín, Yucatán, Mexiko
- Har inte rekryterat ännu
- Centro de Salud Tizimin
-
-
-
-
-
Caledonia, Panama, 7094
- Har inte rekryterat ännu
- CEVAXIN Avenida Mexico
-
La Chorrera, Panama
- Har inte rekryterat ännu
- CEVAXIN Chorrera
-
Panama City, Panama
- Har inte rekryterat ännu
- CEVAXIN 24 de Diciembre
-
Panama City, Panama
- Har inte rekryterat ännu
- Instituto de Investigaciones Cienti-ficas Y Servicios de Alta Tecnologia Asociacion de Interes Panama; . Centro de Investigación, Innovación y Gestión del Conocimiento de Ciudad de la Salud, Caja de Seguro social
-
-
-
-
-
Ponce, Puerto Rico
- Rekrytering
- Ponce Health Sciences University
-
San Juan, Puerto Rico, 00907
- Rekrytering
- BRCR Global
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Participant is male or female, between ≥2 years to <12 years of age for Cohort 1 or ≥6 months to <2 years of age for Cohort 2 (calculated from date of birth) at the time of signing the informed consent/assent.
- Participant is in good general health as determined by medical evaluation including medical history and physical examination. Participants with chronic but stable conditions (eg, gastroesophageal reflux disease, asthma) may be eligible to enroll, provided the condition is well-controlled and not expected to interfere with study participation or outcomes.
- For participants in Cohort 2: the participant was born at ≥37 weeks, with a minimum birth weight of 2.5 kilograms, without fetal growth restriction.
- Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as premenarche. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a participant with an early undetected pregnancy. If childbearing potential is unclear (for example, amenorrhea in athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluation should be considered.
- Female participants who have reached menarche may be enrolled in the study if all of the following criteria are fulfilled:
- Has a negative highly sensitive pregnancy test (urine or serum) as required by local regulations within 24 hours before the study intervention.
- Is not currently chest/breastfeeding.
- Has been using a highly effective contraceptive method or has abstained from all activities that could lead to pregnancy for at least 28 days prior to the study injection (Day 1). The investigator should evaluate the potential for contraceptive method failure (for example, noncompliance, recently initiated) in relationship to the study injection.
- Has agreed to continue adequate contraception through the end of study. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Key Exclusion Criteria:
- History of SARS-CoV-2 infection within 3 months prior to enrollment.
- Acutely ill or febrile (temperature ≥38.0℃elsius [100.4°Fahrenheit]) within 72 hours prior to or at the screening visit or Day 1. Participants who are acutely ill or febrile may be scheduled for a separate dosing visit within the protocol-specified window for screening and will retain their initially assigned participant number. Afebrile participants with minor illnesses can be enrolled at the discretion of the Investigator.
- Any medical, psychiatric, or occupational condition, including reported history of drug, or alcohol abuse in the parent(s)/ legally authorized representative(s), that, in the opinion of the investigator, might pose additional risk due to child's participation in the study, could interfere with safety assessments, or could interfere with the interpretation of study results.
- Receipt of the 2026-2027 formulation of a COVID-19 vaccine at any time prior to enrollment.
- Receipt of any COVID-19 vaccine within 6 months prior to enrollment.
- Receipt of any nonstudy vaccination within 14 days (28 days for live vaccines) prior to study intervention or plans to receive a nonstudy vaccine through 14 days after administration of study intervention.
- Received systemic immunosuppressive treatment, including long-acting biological therapies that affect immune responses (for example, infliximab), within 180 days prior to Day 1 (baseline) or plans to do so during the study.
- Received systemic immunoglobulins or blood products within 90 days prior to the screening visit or plans to receive them during the study. Exception: Nirsevimab and clesrovimab are allowed.
- For infants who receive breast milk, maternal receipt of systemic immunosuppressive therapy during lactation. This includes ≥10 milligrams/day of prednisone or equivalent for 14 days or more, or other immunomodulating agents (for example, biologics, calcineurin inhibitors, disease-modifying agents) that may be transferred via breastmilk and impact infant immune development or vaccine response.
- Has participated in an interventional clinical study within 28 days prior to the screening visit based on the medical history interview or plans to do so while participating in this study.
- Has been placed under the control or protection of an agency, organization, institution, or entity by the courts, the government, or a government body, acting in accordance with powers conferred on them by laws, and regulation. Does not include a child who is adopted or has an appointed legal guardian.
- Receipt of any nonstudy vaccination within 14 days (28 days for live vaccines) prior to study intervention or plans to receive a nonstudy vaccine through 14 days after administration of study intervention.
- History of any myocarditis, pericarditis, or myopericarditis
Note: Other inclusion and exclusion criteria may apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimentell: Cohort 1: mRNA-1283 Dose Level 1
Participants aged 2 to <12 years receive one IM dose of on Day 1. |
Sterile liquid for injection |
|
Experimentell: Cohort 1: mRNA-1283 Dose Level 2
Participants aged 2 to <12 years receive one IM dose of on Day 1. |
Sterile liquid for injection |
|
Aktiv komparator: Cohort 1: mRNA-1273
Participants aged 2 to <12 years receive one IM dose of on Day 1. |
Sterile liquid for injection |
|
Experimentell: Cohort 2: mRNA-1283 Dose Level 1
Participants aged 6 months to <2 years receive two IM doses 28 days apart (Days 1 and 29). |
Sterile liquid for injection |
|
Experimentell: Cohort 2: mRNA-1283 Dose Level 2
Participants aged 6 months to <2 years receive two IM doses of 28 days apart (Days 1 and 29). |
Sterile liquid for injection |
|
Aktiv komparator: Cohort 2: mRNA-1273
Participants aged 6 months to <2 years receive two IM doses 28 days apart (Day 1 and 29). |
Sterile liquid for injection |
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Cohort 1 and Cohort 2: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
Tidsram: Day 1 through Day 7; 7 Days following injection
|
Day 1 through Day 7; 7 Days following injection
|
|
Cohort 1 and Cohort 2: Number of Participants with Unsolicited Adverse Events (AEs)
Tidsram: Day 1 through Day 28 (Cohort 1); 28 Days following injection (Cohort 2)
|
Day 1 through Day 28 (Cohort 1); 28 Days following injection (Cohort 2)
|
|
Cohort 1 and Cohort 2: Number of Participants with Any Medically Attended AEs (MAAEs), Serious AEs (SAEs), AEs of Special Interest (AESIs), and AEs Leading to Discontinuation from the Study
Tidsram: Day 1 through End of Study (Month 13)
|
Day 1 through End of Study (Month 13)
|
|
Cohort 1 and Cohort 2: Geometric Mean Value of Antibody Level Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Target Variant
Tidsram: Day 29 VISIT (Cohort 1), Day 57 VISIT (Cohort 2)
|
Day 29 VISIT (Cohort 1), Day 57 VISIT (Cohort 2)
|
|
Cohort 1 and Cohort 2: Geometric Mean Fold Rise of Antibody Level Against SARS-CoV-2
Tidsram: Day 29 (Cohort 1), Day 57 (Cohort 2)
|
Day 29 (Cohort 1), Day 57 (Cohort 2)
|
|
Cohort 1 and Cohort 2: Number of Participants with Seroresponse Rate
Tidsram: Day 29 (Cohort 1), Day 57 (Cohort 2)
|
Day 29 (Cohort 1), Day 57 (Cohort 2)
|
Samarbetspartners och utredare
Sponsor
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Studiestart
Primärt slutförande (Beräknad)
Primärt slutförande
Avslutad studie (Beräknad)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Luftvägsinfektioner
- Infektioner
- RNA-virusinfektioner
- Luftvägssjukdomar
- Lungsjukdomar
- Lunginflammation, Viral
- Lunginflammation
- Coronaviridae-infektioner
- Nidovirales infektioner
- Covid-19
- Virussjukdomar
- Coronavirusinfektioner
- Aminosyror, peptider och proteiner
- Proteiner
- Biologiska faktorer
- Biologiska produkter
- Komplexa blandningar
- Vacciner
- Virala vacciner
- mRNA -vacciner
- Nukleinsyrabaserade vacciner
- Vacciner, syntetiska
- Rekombinant proteiner
- Covid-19 vacciner
- Antigen
- 2019-NCOV-vaccin mRNA-1273
Andra studie-ID-nummer
Andra studie-ID-nummer
- mRNA-1283-P202
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .